Who are Perindopril plus Hydrochlorothiazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Benazepril plus hydrochlorothiazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/perindopril-plus-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Perindopril plus Hydrochlorothiazide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Perindopril plus Hydrochlorothiazide (Perindopril plus Hydrochlorothiazide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor plus thiazide diuretic combination. Area: Cardiovascular.

marketed ACE inhibitor plus thiazide diuretic combination Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter in the distal convoluted tubule Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Perindopril plus Hydrochlorothiazide (Perindopril plus Hydrochlorothiazide) — University of Abuja. Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and aldosterone secretion, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Perindopril plus Hydrochlorothiazide TARGET	Perindopril plus Hydrochlorothiazide	University of Abuja	marketed	ACE inhibitor plus thiazide diuretic combination	Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter in the distal convoluted tubule
Benazepril plus hydrochlorothiazide	Benazepril plus hydrochlorothiazide	Novartis	phase 3	ACE inhibitor plus thiazide diuretic combination	Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor plus thiazide diuretic combination class)

Novartis · 1 drug in this class
University of Abuja · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Perindopril plus Hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/perindopril-plus-hydrochlorothiazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab